Vigil Neuroscience Insider Filing Confirms $8 Cash-Out in Sanofi Deal
Rhea-AI Filing Summary
Vigil Neuroscience, Inc. (VIGL) – Form 4 filing (08/05/2025)
Chief Medical Officer Dr. Petra Kaufmann reported the disposition of all outstanding stock options in connection with the closing of the merger between Vigil and Sanofi. At the 08/05/2025 effective time, Sanofi’s wholly-owned subsidiary merged with Vigil, making Vigil a wholly-owned Sanofi unit.
- Cash consideration to shareholders: every Vigil common share was converted into $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon a specified clinical milestone.
- Options cancelled & cashed-out: 144,000 options (exercise $2.19) and 330,000 options (exercise $3.14) were cancelled. Holders receive cash equal to the spread versus $8.00 plus one CVR per underlying share.
- Acceleration: all unvested options became fully vested before cancellation.
- Following the transaction, Dr. Kaufmann reports zero derivative securities remaining.
The filing confirms consummation of the Sanofi acquisition and crystallises value for option holders and common shareholders.
Positive
- Merger consummation confirmed: shareholders receive $8.00 cash per share plus a $2.00 CVR, crystallising value.
- Immediate monetisation for employees: all unvested options accelerated and paid out at a premium to exercise price.
Negative
- None.
Insights
TL;DR: Form 4 confirms Sanofi’s takeover closed; insiders cashed-out, shareholders get $8 cash + $2 CVR, eliminating remaining stand-alone equity.
The disclosure is mechanically routine yet material because it evidences legal completion of the merger, final economics ($8 cash + $2 CVR) and option treatment. Unvested grants were accelerated, then cash-settled—standard in change-of-control deals but positive for employees and investors, as value is realised immediately. Remaining beneficial ownership is zero, indicating Vigil equity migrates entirely to Sanofi. For public holders, trading in VIGL will cease once the conversion is processed. The CVR provides upside tied to a clinical milestone, adding contingent value. Overall impact: favourable confirmation of merger closing and payout certainty.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option Award (Right to Buy) | 144,000 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 330,000 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.
